MarketPR
MARKETSPomerantz LLP investigates investor claims against Ionis Pharmaceuticals (IONS)Jul 17$ETHBitmine Immersion Technologies holds 5.77 million ETH, equal to 4.8% of total Ethereum supplyJul 17MARKETSKalshi traders price a 54% chance of a Fed rate hike before 2027Jul 17MARKETSPATK puts July 30 on the calendar: Patrick Industries confirms pre-market Q2 earnings date and webcastJul 17MARKETSStellus Private Credit BDC sets $0.31 Q3 2026 dividend in monthly installments of $0.1033Jul 16MARKETSDFIN marks July 30 for second-quarter results and investor callJul 16MARKETSPaymonade clears MiCA as roughly 90% of Europe's crypto firms fail the thresholdJul 16MARKETSTomorrowland Belgium 2026 livestream lands on the KuCoin App, both festival weekends coveredJul 16MARKETSPomerantz class action names ChampionX Corporation; CHX investors face upcoming deadlinesJul 16MARKETSArchy Revenue targets dental billing backlog with AI-powered payment postingJul 16MARKETSPomerantz LLP investigates investor claims against Ionis Pharmaceuticals (IONS)Jul 17$ETHBitmine Immersion Technologies holds 5.77 million ETH, equal to 4.8% of total Ethereum supplyJul 17MARKETSKalshi traders price a 54% chance of a Fed rate hike before 2027Jul 17MARKETSPATK puts July 30 on the calendar: Patrick Industries confirms pre-market Q2 earnings date and webcastJul 17MARKETSStellus Private Credit BDC sets $0.31 Q3 2026 dividend in monthly installments of $0.1033Jul 16MARKETSDFIN marks July 30 for second-quarter results and investor callJul 16MARKETSPaymonade clears MiCA as roughly 90% of Europe's crypto firms fail the thresholdJul 16MARKETSTomorrowland Belgium 2026 livestream lands on the KuCoin App, both festival weekends coveredJul 16MARKETSPomerantz class action names ChampionX Corporation; CHX investors face upcoming deadlinesJul 16MARKETSArchy Revenue targets dental billing backlog with AI-powered payment postingJul 16
NewsMacro

Pomerantz LLP investigates investor claims against Ionis Pharmaceuticals (IONS)

A securities plaintiff firm has put Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) in focus. Pomerantz LLP disclosed on July 16, 2026, that it is investigating claims on behalf of investors in the NASDAQ-listed company. The firm named Danielle Peyton as the point of contact, reachable at [email protected] or 646-581-9980, ext. 7980.

By Lena ParkMacro DeskJuly 17, 20262 min read
Share

A securities plaintiff firm has put Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) in focus. Pomerantz LLP disclosed on July 16, 2026, that it is investigating claims on behalf of investors in the NASDAQ-listed company. The firm named Danielle Peyton as the point of contact, reachable at [email protected] or 646-581-9980, ext. 7980.

What the disclosure contains

The announcement was issued from New York via PRNewswire on July 16, 2026. Pomerantz identified Ionis Pharmaceuticals by its full legal name and NASDAQ ticker. The firm offered no information about what triggered the inquiry, the nature of the claims, or the time period at issue. The disclosure is limited to the fact of the investigation and contact details for affected investors.

What to watch

The next material development would be a formal complaint, if Pomerantz elects to file one. That document would identify the class period, the allegations, and the legal theory. Nothing of that kind has been announced. For investors who believe they may have a claim, the firm's designated contact is Danielle Peyton at 646-581-9980, ext. 7980, or [email protected].

About this story

Filed by the macro desk of MarketPR on July 17, 2026. Source: MarketPR. Indicative figures are not investment advice.

←Back to the news index

More from the Newsroom

All stories →
01Macro · $ETH

Bitmine Immersion Technologies holds 5.77 million ETH, equal to 4.8% of total Ethereum supply

The filing put $ETH in focus: Bitmine Immersion Technologies (BMNR) disclosed Ethereum holdings of 5.77 million tokens, a stake equal to 4.8% of the coin's total outstanding supply of 120.7 million. The company's combined crypto and cash position reaches $11.3 billion.

Marcus Cole2 min read
02Macro

Kalshi traders price a 54% chance of a Fed rate hike before 2027

Wednesday's Federal Reserve minutes arrived with a divided committee and no agreed signal on rates, and Kalshi's prediction market has translated that ambiguity into a number: [a 54% probability of a hike before 2027](/news/fed-july-rate-hike-odds-climb-as-oil-jumps-on-strait-of-

Jonah Berg2 min read
03Macro

PATK puts July 30 on the calendar: Patrick Industries confirms pre-market Q2 earnings date and webcast

A second-quarter earnings date is now set for Patrick Industries (NASDAQ: PATK): results for the second quarter and the first six months of 2026 land before the opening bell on Thursday, July 30, 2026, with a [conference call webcast](/news/dfin-marks-july-30-for-second-quarter-r

Grace Osei2 min read

Key takeaways

Frequently asked

Who is investigating Ionis Pharmaceuticals and when was it announced?

Pomerantz LLP disclosed on July 16, 2026, that it is investigating claims on behalf of investors in Ionis Pharmaceuticals (NASDAQ: IONS).

What specific allegations has Pomerantz made against Ionis?

The firm offered no information about what triggered the inquiry, the nature of the claims, or the time period at issue; the disclosure is limited to the fact of the investigation.

How can affected investors contact the firm?

Investors can reach the designated contact, Danielle Peyton, at [email protected] or 646-581-9980, ext. 7980.

Has a lawsuit been filed against Ionis Pharmaceuticals?

No, a formal complaint would be the next material development if Pomerantz elects to file one, but nothing of that kind has been announced.

What would a formal complaint reveal if one is filed?

It would identify the class period, the allegations, and the legal theory.